加载中…
Anti-CD44 Antibody (Bivatuzumab Biosimilar) is a research-use biosimilar antibody expressed in HEK293. The source page specifies target CD44, reactivity Human/Cynomolgus, isotype Human IgG1-Kappa, source-listed application ELISA.
CD44 is a hyaluronan binding cell surface signal transducing receptor that influences motility, cell survival and proliferation as well as the formation of tumor microenvironment. CD44 contains two variable regions encoded by variable exons. Alternative splicing, which is often deregulated in cancer, can produce various isoforms of CD44 with properties that may have different tissue specific effects and therefore even diverse effects on cancer progression
